Epistaxis medical therapy: Difference between revisions

Jump to navigation Jump to search
No edit summary
No edit summary
Line 9: Line 9:


==Medical Therapy==
==Medical Therapy==
If nasal bleeding is active and nasal compression couldn't stop [[bleeding]], there are the following medical options:<ref name="TunkelAnne2020">{{cite journal|last1=Tunkel|first1=David E.|last2=Anne|first2=Samantha|last3=Payne|first3=Spencer C.|last4=Ishman|first4=Stacey L.|last5=Rosenfeld|first5=Richard M.|last6=Abramson|first6=Peter J.|last7=Alikhaani|first7=Jacqueline D.|last8=Benoit|first8=Margo McKenna|last9=Bercovitz|first9=Rachel S.|last10=Brown|first10=Michael D.|last11=Chernobilsky|first11=Boris|last12=Feldstein|first12=David A.|last13=Hackell|first13=Jesse M.|last14=Holbrook|first14=Eric H.|last15=Holdsworth|first15=Sarah M.|last16=Lin|first16=Kenneth W.|last17=Lind|first17=Meredith Merz|last18=Poetker|first18=David M.|last19=Riley|first19=Charles A.|last20=Schneider|first20=John S.|last21=Seidman|first21=Michael D.|last22=Vadlamudi|first22=Venu|last23=Valdez|first23=Tulio A.|last24=Nnacheta|first24=Lorraine C.|last25=Monjur|first25=Taskin M.|title=Clinical Practice Guideline: Nosebleed (Epistaxis)|journal=Otolaryngology–Head and Neck Surgery|volume=162|issue=1_suppl|year=2020|pages=S1–S38|issn=0194-5998|doi=10.1177/0194599819890327}}</ref> <ref name="KremplNoorily2016">{{cite journal|last1=Krempl|first1=Greg A.|last2=Noorily|first2=Allen D.|title=Use of Oxymetazoline in the Management of Epistaxis|journal=Annals of Otology, Rhinology & Laryngology|volume=104|issue=9|year=2016|pages=704–706|issn=0003-4894|doi=10.1177/000348949510400906}}</ref> <ref name="MontastrucMontastruc2014">{{cite journal|last1=Montastruc|first1=François|last2=Montastruc|first2=Guillaume|last3=Taudou|first3=Marie-Josée|last4=Olivier-Abbal|first4=Pascale|last5=Montastruc|first5=Jean-Louis|last6=Bondon-Guitton|first6=Emmanuelle|title=Acute Coronary Syndrome After Nasal Spray of Oxymetazoline|journal=Chest|volume=146|issue=6|year=2014|pages=e214–e215|issn=00123692|doi=10.1378/chest.14-1873}}</ref> <ref name="KrulewitzFix2019">{{cite journal|last1=Krulewitz|first1=Neil Alexander|last2=Fix|first2=Megan Leigh|title=Epistaxis|journal=Emergency Medicine Clinics of North America|volume=37|issue=1|year=2019|pages=29–39|issn=07338627|doi=10.1016/j.emc.2018.09.005}}</ref> <ref name="DouglasWormald2007">{{cite journal|last1=Douglas|first1=Richard|last2=Wormald|first2=Peter-John|title=Update on epistaxis|journal=Current Opinion in Otolaryngology & Head and Neck Surgery|volume=15|issue=3|year=2007|pages=180–183|issn=1068-9508|doi=10.1097/MOO.0b013e32814b06ed}}</ref>


* General management of patients is important. Stabilizing the patient and treating the specific cause is the basis of management.<ref name="TunkelAnne2020">{{cite journal|last1=Tunkel|first1=David E.|last2=Anne|first2=Samantha|last3=Payne|first3=Spencer C.|last4=Ishman|first4=Stacey L.|last5=Rosenfeld|first5=Richard M.|last6=Abramson|first6=Peter J.|last7=Alikhaani|first7=Jacqueline D.|last8=Benoit|first8=Margo McKenna|last9=Bercovitz|first9=Rachel S.|last10=Brown|first10=Michael D.|last11=Chernobilsky|first11=Boris|last12=Feldstein|first12=David A.|last13=Hackell|first13=Jesse M.|last14=Holbrook|first14=Eric H.|last15=Holdsworth|first15=Sarah M.|last16=Lin|first16=Kenneth W.|last17=Lind|first17=Meredith Merz|last18=Poetker|first18=David M.|last19=Riley|first19=Charles A.|last20=Schneider|first20=John S.|last21=Seidman|first21=Michael D.|last22=Vadlamudi|first22=Venu|last23=Valdez|first23=Tulio A.|last24=Nnacheta|first24=Lorraine C.|last25=Monjur|first25=Taskin M.|title=Clinical Practice Guideline: Nosebleed (Epistaxis)|journal=Otolaryngology–Head and Neck Surgery|volume=162|issue=1_suppl|year=2020|pages=S1–S38|issn=0194-5998|doi=10.1177/0194599819890327}}</ref> <ref name="KremplNoorily2016">{{cite journal|last1=Krempl|first1=Greg A.|last2=Noorily|first2=Allen D.|title=Use of Oxymetazoline in the Management of Epistaxis|journal=Annals of Otology, Rhinology & Laryngology|volume=104|issue=9|year=2016|pages=704–706|issn=0003-4894|doi=10.1177/000348949510400906}}</ref><ref name="MontastrucMontastruc2014">{{cite journal|last1=Montastruc|first1=François|last2=Montastruc|first2=Guillaume|last3=Taudou|first3=Marie-Josée|last4=Olivier-Abbal|first4=Pascale|last5=Montastruc|first5=Jean-Louis|last6=Bondon-Guitton|first6=Emmanuelle|title=Acute Coronary Syndrome After Nasal Spray of Oxymetazoline|journal=Chest|volume=146|issue=6|year=2014|pages=e214–e215|issn=00123692|doi=10.1378/chest.14-1873}}</ref>
* <br />General management of patients is important. Stabilizing the patient and treating the specific cause is the basis of management.


*<br />At first [[Airway]] , [[breathing]] and [[circulation]] should be evaluated.


'''Medical Therapy:'''


*'''[[Vasoconstrictors]]''' (Use with caution in children and patients with [[glaucoma]], [[Hypertension|HTN]],  [[peripheral vasoconstriction]], [[Cardiac disease|cardiac diseases]] and [[cerebrovascular]] problems):
**Preferred regimen (1): [[Oxymetazoline]] 0.05% [[intranasal]] [[spray]]. In children <6 years just with [[physicians]] suggestion.
**Alternative regimen (1): [[Phenylephrine]] 0.25% [[intranasal spray]]. In children ≥2 years Phenylephrine 0.125% nasal solution can be used.
**Alternative regimen (2): [[Epinephrine]] 1:100,000 with [[Lidocaine]] 1% (Topical ).


* <br />At first [[Airway]] , [[breathing]] and [[circulation]] should be evaluated.  
*'''[[Antifibrinolytic]]''':
**Preferred regimen (1): [[Tranexamic acid]] ([[Tranexamic acid|TXA]]) (Topical ).<br />


If nasal bleeding is active and nasal compression couldn't stop [[bleeding]], there are the following medical options:
*'''[[Chemical]] [[cauterization]]''' ( At first [[anesthesia]] [[bleeding]] site and limit nasal [[cautery]] to site''':'''  
**Preferred regimen (1): [[Silver nitrate]] 25%-75%
**Alternative regimen (1): [[Chromic acid]]
**Alternative regimen (2): [[Trichloroacetic acid]]


* '''[[Vasoconstrictors]]''' (Use with caution in children and patients with [[glaucoma]], [[Hypertension|HTN]],  [[peripheral vasoconstriction]], [[Cardiac disease|cardiac diseases]] and [[cerebrovascular]] problems):
*Some [[Medicine|medicines]] are used to prevent [[epistaxis]]:
** Preferred regimen (1): [[Oxymetazoline]] 0.05% [[intranasal]] [[spray]]. In children <6 years just with [[physicians]] suggestion.
**'''[[Emollient]] [[Cream (pharmaceutical)|creams]] :''' Continues using of topical [[emollient]] [[Cream (pharmaceutical)|creams]] is useful to prevent [[epistaxis]].
** Alternative regimen (1): [[Phenylephrine]] 0.25% [[intranasal spray]]. In children ≥2 years Phenylephrine 0.125% nasal solution can be used.
**'''[[Ointment|Ointments]] :''' Continues using of topical [[Ointment|ointments]] is useful to prevent [[epistaxis]]
** Alternative regimen (2): [[Epinephrine]] 1:100,000 with [[Lidocaine]] 1% (Topical ).
 
* '''[[Antifibrinolytic]]''':
** Preferred regimen (1): [[Tranexamic acid]] ([[Tranexamic acid|TXA]]) (Topical ).<br />
 
* '''[[Chemical]] [[cauterization]]''' ( At first [[anesthesia]] [[bleeding]] site and limit nasal [[cautery]] to site''':'''
** Preferred regimen (1): [[Silver nitrate]] 25%-75%
** Alternative regimen (1): [[Chromic acid]]
** Alternative regimen (2): [[Trichloroacetic acid]]
 
* Some [[Medicine|medicines]] are used to prevent [[epistaxis]]:
** '''[[Emollient]] [[Cream (pharmaceutical)|creams]] :''' Continues using of topical [[emollient]] [[Cream (pharmaceutical)|creams]] is useful to prevent [[epistaxis]].
** '''[[Ointment|Ointments]] :''' Continues using of topical [[Ointment|ointments]] is useful to prevent [[epistaxis]]


==References==
==References==

Revision as of 20:30, 27 October 2020

Epistaxis Microchapters

Home

Patient Information

Overview

Historical Perspective

Classification

Pathophysiology

Causes

Differentiating Epistaxis from other Diseases

Epidemiology and Demographics

Risk Factors

Screening

Natural History, Complications and Prognosis

Diagnosis

Diagnostic Study of Choice

History and Symptoms

Physical Examination

Laboratory Findings

Electrocardiogram

X-ray

Echocardiography and Ultrasound

CT Scan

Other Imaging Findings

Other Diagnostic Studies

Treatment

Medical Therapy

Surgery

Primary Prevention

Secondary Prevention

Cost-Effectiveness of Therapy

Future or Investigational Therapies

Case Studies

Case #1

Epistaxis medical therapy On the Web

Most recent articles

Most cited articles

Review articles

CME Programs

Powerpoint slides

Images

American Roentgen Ray Society Images of Epistaxis medical therapy

All Images
X-rays
Echo & Ultrasound
CT Images
MRI

Ongoing Trials at Clinical Trials.gov

US National Guidelines Clearinghouse

NICE Guidance

FDA on Epistaxis medical therapy

CDC on Epistaxis medical therapy

Epistaxis medical therapy in the news

Blogs on Epistaxis medical therapy

Directions to Hospitals Treating Epistaxis

Risk calculators and risk factors for Epistaxis medical therapy

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1] ; Associate Editor(s)-in-Chief:Amir Behzad Bagheri, M.D.


Overview

Most of the time no action is needed to stop epistaxis. In active bleeding nasal compression is the first line to stop bleeding. If bleeding continues there are other options like cautery and some vasoconstrictive agents like oxymetazoline or phenylephrine to control bleeding.

Medical Therapy

If nasal bleeding is active and nasal compression couldn't stop bleeding, there are the following medical options:[1] [2] [3] [4] [5]


  • General management of patients is important. Stabilizing the patient and treating the specific cause is the basis of management.

Medical Therapy:

References

  1. Tunkel, David E.; Anne, Samantha; Payne, Spencer C.; Ishman, Stacey L.; Rosenfeld, Richard M.; Abramson, Peter J.; Alikhaani, Jacqueline D.; Benoit, Margo McKenna; Bercovitz, Rachel S.; Brown, Michael D.; Chernobilsky, Boris; Feldstein, David A.; Hackell, Jesse M.; Holbrook, Eric H.; Holdsworth, Sarah M.; Lin, Kenneth W.; Lind, Meredith Merz; Poetker, David M.; Riley, Charles A.; Schneider, John S.; Seidman, Michael D.; Vadlamudi, Venu; Valdez, Tulio A.; Nnacheta, Lorraine C.; Monjur, Taskin M. (2020). "Clinical Practice Guideline: Nosebleed (Epistaxis)". Otolaryngology–Head and Neck Surgery. 162 (1_suppl): S1–S38. doi:10.1177/0194599819890327. ISSN 0194-5998.
  2. Krempl, Greg A.; Noorily, Allen D. (2016). "Use of Oxymetazoline in the Management of Epistaxis". Annals of Otology, Rhinology & Laryngology. 104 (9): 704–706. doi:10.1177/000348949510400906. ISSN 0003-4894.
  3. Montastruc, François; Montastruc, Guillaume; Taudou, Marie-Josée; Olivier-Abbal, Pascale; Montastruc, Jean-Louis; Bondon-Guitton, Emmanuelle (2014). "Acute Coronary Syndrome After Nasal Spray of Oxymetazoline". Chest. 146 (6): e214–e215. doi:10.1378/chest.14-1873. ISSN 0012-3692.
  4. Krulewitz, Neil Alexander; Fix, Megan Leigh (2019). "Epistaxis". Emergency Medicine Clinics of North America. 37 (1): 29–39. doi:10.1016/j.emc.2018.09.005. ISSN 0733-8627.
  5. Douglas, Richard; Wormald, Peter-John (2007). "Update on epistaxis". Current Opinion in Otolaryngology & Head and Neck Surgery. 15 (3): 180–183. doi:10.1097/MOO.0b013e32814b06ed. ISSN 1068-9508.

Template:WikiDoc Sources